Driver mutations in primary myelofibrosis and their implications

Natasha Szuber, Ayalew Tefferi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of review Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN). Oncogenic driver mutations in PMF include Janus kinase 2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene. These mutations are not only pathogenetically relevant but might also influence disease outcome. Our objective for the current communication is to comprehensively review the distinct phenotypic, therapeutic, and prognostic implications of driver mutations in PMF. Recent findings The discovery of driver mutations has revolutionized our understanding of pathogenic mechanisms and clinical heterogeneity in MPN, including PMF. Recently, there have been further advances in our knowledge of the molecular pathogenesis of MPN, particularly pertaining to CALR and its mutation. Moreover, the type and number of additional mutations, their order of acquisition, and their myriad combinatorial interactions with driver mutations may have dynamic pathogenic and clinical consequences. There are also additional data supporting the role of these genetic lesions and their associated allele burdens in modulating clinical features, including outcomes following treatment. Summary Literature exists to support both phenotypic and prognostic correlates of conventional driver mutations in PMF. As the genetic landscape becomes increasingly complex, establishing the functional impact of these mutations and defining their interactions with other molecular, cytogenetic, and extrinsic factors will further our insight and potentially alter our clinical approach.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalCurrent Opinion in Hematology
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Primary Myelofibrosis
Mutation
Calreticulin
Janus Kinase 2
Neoplasms
Oncogenes
Cytogenetics
Leukemia
Alleles
Viruses

Keywords

  • driver mutations
  • pathogenesis
  • primary myelofibrosis
  • prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Driver mutations in primary myelofibrosis and their implications. / Szuber, Natasha; Tefferi, Ayalew.

In: Current Opinion in Hematology, Vol. 25, No. 2, 01.03.2018, p. 129-135.

Research output: Contribution to journalReview article

@article{d1381fe73a9d4cbab96ec39a48b3f759,
title = "Driver mutations in primary myelofibrosis and their implications",
abstract = "Purpose of review Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN). Oncogenic driver mutations in PMF include Janus kinase 2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene. These mutations are not only pathogenetically relevant but might also influence disease outcome. Our objective for the current communication is to comprehensively review the distinct phenotypic, therapeutic, and prognostic implications of driver mutations in PMF. Recent findings The discovery of driver mutations has revolutionized our understanding of pathogenic mechanisms and clinical heterogeneity in MPN, including PMF. Recently, there have been further advances in our knowledge of the molecular pathogenesis of MPN, particularly pertaining to CALR and its mutation. Moreover, the type and number of additional mutations, their order of acquisition, and their myriad combinatorial interactions with driver mutations may have dynamic pathogenic and clinical consequences. There are also additional data supporting the role of these genetic lesions and their associated allele burdens in modulating clinical features, including outcomes following treatment. Summary Literature exists to support both phenotypic and prognostic correlates of conventional driver mutations in PMF. As the genetic landscape becomes increasingly complex, establishing the functional impact of these mutations and defining their interactions with other molecular, cytogenetic, and extrinsic factors will further our insight and potentially alter our clinical approach.",
keywords = "driver mutations, pathogenesis, primary myelofibrosis, prognosis",
author = "Natasha Szuber and Ayalew Tefferi",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/MOH.0000000000000406",
language = "English (US)",
volume = "25",
pages = "129--135",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Driver mutations in primary myelofibrosis and their implications

AU - Szuber, Natasha

AU - Tefferi, Ayalew

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of review Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN). Oncogenic driver mutations in PMF include Janus kinase 2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene. These mutations are not only pathogenetically relevant but might also influence disease outcome. Our objective for the current communication is to comprehensively review the distinct phenotypic, therapeutic, and prognostic implications of driver mutations in PMF. Recent findings The discovery of driver mutations has revolutionized our understanding of pathogenic mechanisms and clinical heterogeneity in MPN, including PMF. Recently, there have been further advances in our knowledge of the molecular pathogenesis of MPN, particularly pertaining to CALR and its mutation. Moreover, the type and number of additional mutations, their order of acquisition, and their myriad combinatorial interactions with driver mutations may have dynamic pathogenic and clinical consequences. There are also additional data supporting the role of these genetic lesions and their associated allele burdens in modulating clinical features, including outcomes following treatment. Summary Literature exists to support both phenotypic and prognostic correlates of conventional driver mutations in PMF. As the genetic landscape becomes increasingly complex, establishing the functional impact of these mutations and defining their interactions with other molecular, cytogenetic, and extrinsic factors will further our insight and potentially alter our clinical approach.

AB - Purpose of review Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN). Oncogenic driver mutations in PMF include Janus kinase 2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene. These mutations are not only pathogenetically relevant but might also influence disease outcome. Our objective for the current communication is to comprehensively review the distinct phenotypic, therapeutic, and prognostic implications of driver mutations in PMF. Recent findings The discovery of driver mutations has revolutionized our understanding of pathogenic mechanisms and clinical heterogeneity in MPN, including PMF. Recently, there have been further advances in our knowledge of the molecular pathogenesis of MPN, particularly pertaining to CALR and its mutation. Moreover, the type and number of additional mutations, their order of acquisition, and their myriad combinatorial interactions with driver mutations may have dynamic pathogenic and clinical consequences. There are also additional data supporting the role of these genetic lesions and their associated allele burdens in modulating clinical features, including outcomes following treatment. Summary Literature exists to support both phenotypic and prognostic correlates of conventional driver mutations in PMF. As the genetic landscape becomes increasingly complex, establishing the functional impact of these mutations and defining their interactions with other molecular, cytogenetic, and extrinsic factors will further our insight and potentially alter our clinical approach.

KW - driver mutations

KW - pathogenesis

KW - primary myelofibrosis

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85042434097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042434097&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000406

DO - 10.1097/MOH.0000000000000406

M3 - Review article

VL - 25

SP - 129

EP - 135

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -